MYOK MyoKardia Inc.

44.2
-2.68  -6%
Previous Close 46.88
Open 45.74
Price To Book 5.07
Market Cap 2,058,594,580
Shares 46,574,538
Volume 790,769
Short Ratio
Av. Daily Volume 459,391
Stock charts supplied by TradingView

NewsSee all news

  1. MyoKardia Announces Mavacamten Treatment Well Tolerated and Significantly Reduced Biomarkers of Cardiac Injury and Wall Stress in Non-Obstructive Hypertrophic Cardiomyopathy Patients

    MAVERICK-HCM Phase 2 Clinical Trial Results Consistent with Tolerability Observations from Prior Studies of Mavacamten Improvement in NT-proBNP and Troponin Levels Support Future Development in Non-Obstructive HCM and

  2. MyoKardia Provides Clinical Trial Update in the Context of the COVID-19 Pandemic

    BRISBANE, Calif., March 26, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (NASDAQ:MYOK) today provided an update to the status of its clinical programs in the context of the COVID-19 (coronavirus) pandemic given the impact

  3. Data from MAVERICK-HCM Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy Selected for Virtual Late-Breaker Presentation at the American College of Cardiology's 69th Annual Scientific Session Together with World Congress of Cardiology

    BRISBANE, Calif., March 19, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (NASDAQ:MYOK) today announced that the company will be presenting data from its Phase 2 MAVERICK-HCM clinical trial during a late-breaker session at

  4. MyoKardia Reports Fourth Quarter and Full Year 2019 Financial Results

    BRISBANE, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (NASDAQ:MYOK), today reported financial results for the fourth quarter and full year ended December 31, 2019. "MyoKardia achieved significant

  5. MyoKardia to Present at 40th Annual Cowen Health Care Conference

    BRISBANE, Calif., Feb. 24, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (NASDAQ:MYOK), today announced that Taylor Harris, Chief Financial Officer, will present at the 40th Annual Cowen Health Care Conference on Monday,

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data due 2Q 2020.
Mavacamten (MYK-461) - EXPLORER-HCM
Hypertrophic cardiomyopathy (HCM)
Phase 2 updated data released November 11, 2019.
Mavacamten (MYK-461) - PIONEER-OLE
Non-obstructive Hypertrophic cardiomyopathy (HCM)
Phase 2 top-line data met primary endpoint.
Mavacamten (MYK-461) - MAVERICK-HCM
Hypertrophic cardiomyopathy (HCM)
Phase 2 trial initiation has been delayed due to COVID-19.
Danicamtiv (MYK-491)
Dilated cardiomyopathy (DCM)
Phase 1 enrolment has been suspended due to COVID-19.
MYK-224
Hypertrophic cardiomyopathy (HCM)

Latest News

  1. MyoKardia Announces Mavacamten Treatment Well Tolerated and Significantly Reduced Biomarkers of Cardiac Injury and Wall Stress in Non-Obstructive Hypertrophic Cardiomyopathy Patients

    MAVERICK-HCM Phase 2 Clinical Trial Results Consistent with Tolerability Observations from Prior Studies of Mavacamten Improvement in NT-proBNP and Troponin Levels Support Future Development in Non-Obstructive HCM and

  2. MyoKardia Provides Clinical Trial Update in the Context of the COVID-19 Pandemic

    BRISBANE, Calif., March 26, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (NASDAQ:MYOK) today provided an update to the status of its clinical programs in the context of the COVID-19 (coronavirus) pandemic given the impact

  3. Data from MAVERICK-HCM Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy Selected for Virtual Late-Breaker Presentation at the American College of Cardiology's 69th Annual Scientific Session Together with World Congress of Cardiology

    BRISBANE, Calif., March 19, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (NASDAQ:MYOK) today announced that the company will be presenting data from its Phase 2 MAVERICK-HCM clinical trial during a late-breaker session at

  4. MyoKardia Reports Fourth Quarter and Full Year 2019 Financial Results

    BRISBANE, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (NASDAQ:MYOK), today reported financial results for the fourth quarter and full year ended December 31, 2019. "MyoKardia achieved significant

  5. MyoKardia to Present at 40th Annual Cowen Health Care Conference

    BRISBANE, Calif., Feb. 24, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (NASDAQ:MYOK), today announced that Taylor Harris, Chief Financial Officer, will present at the 40th Annual Cowen Health Care Conference on Monday,

  6. MyoKardia to Report Fourth Quarter and Full Year 2019 Financial Results on Thursday, February 27, 2020

    BRISBANE, Calif., Feb. 20, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (NASDAQ:MYOK), today announced that it will report fourth quarter and full year 2019 financial and operating results on Thursday, February 27, 2020.

  7. MyoKardia to Present at 38th Annual J.P. Morgan Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Jan. 06, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (NASDAQ:MYOK), today announced that Tassos Gianakakos, Chief Executive Officer, will present at the 38th Annual J.P. Morgan Healthcare

  8. MyoKardia to Present at Evercore ISI 2nd Annual HealthCONx Conference

    SOUTH SAN FRANCISCO, Calif., Nov. 27, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (NASDAQ:MYOK), today announced that Tassos Gianakakos, Chief Executive Officer, will participate in a fireside chat at the Evercore ISI 2nd

  9. MyoKardia Announces 48-week Data from PIONEER-OLE Study of Mavacamten

    Mavacamten's Safety and Efficacy Profile in the PIONEER Study Maintained Through One Year in Open-Label Extension Study of 12 Patients with Symptomatic, Obstructive HCM Evidence Suggests Mavacamten's Favorable Impact on

  10. MyoKardia Announces Positive Topline Data from its Phase 2 MAVERICK-HCM Clinical Trial of Mavacamten

    Achieved Primary Study Objective of Safety and Tolerability in Patients with Non-obstructive HCM Significant Reductions in Biomarkers of Cardiac Stress Observed in Patients on Treatment vs. Placebo Data Support

  11. MyoKardia to Present at Credit Suisse 28th Annual Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (NASDAQ:MYOK), today announced that Tassos Gianakakos, Chief Executive Officer, will participate in a fireside chat at the Credit Suisse

  12. MyoKardia Reports Third Quarter 2019 Financial Results

    SOUTH SAN FRANCISCO, Calif., Nov. 04, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (NASDAQ:MYOK), today reported financial results for the quarter ended September 30, 2019. "As we look across the milestones recently

  13. MyoKardia Announces Abstracts Selected for Presentation at the American Heart Association Scientific Sessions 2019

    SOUTH SAN FRANCISCO, Calif., Nov. 04, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (NASDAQ:MYOK), today announced the presentation of several abstracts at the upcoming American Heart Association (AHA) Scientific Sessions

  14. MyoKardia to Present at 2019 Cantor Global Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (NASDAQ:MYOK), today announced that Taylor Harris, Chief Financial Officer, will participate in a fireside chat at the 2019 Cantor Global

  15. MyoKardia to Evaluate Mavacamten as an Alternative to Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy Patients

    SOUTH SAN FRANCISCO, Calif., Sept. 10, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (NASDAQ:MYOK), today announced that it will study mavacamten as a therapeutic alternative to septal reduction therapy (SRT). The study

  16. MyoKardia Presents 36-week Data from PIONEER-OLE Study of Mavacamten at the European Society of Cardiology Congress 2019

    Durability of Mavacamten's Safety and Efficacy Profile Demonstrated through Nine Months in this Study of Patients with Symptomatic, Obstructive HCM Statistically Significant Changes in Key Biomarkers Maintained,

  17. MyoKardia to Participate in September Investor Conferences

    SOUTH SAN FRANCISCO, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (NASDAQ:MYOK), today announced its participation in the following upcoming investor conferences: Citi 14th Annual Biotech Conference in

  18. MyoKardia Announces Abstracts Selected for Presentation at the European Society of Cardiology Congress 2019

    SOUTH SAN FRANCISCO, Calif., Aug. 26, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (NASDAQ:MYOK) today announced the presentation of three abstracts at the upcoming European Society of Cardiology (ESC) Congress taking